Adjuvantation of whole-killed Leishmania vaccine with anti-CD200 and anti-CD300a antibodies potentiates its efficacy and provides protection against wild-type parasites
Molecular Immunology · 2023
DOI: 10.1016/j.molimm.2023.09.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Immunology, 2023. Verfasst von Rajan Singh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India. Hauptthemen laut MEDLINE: Leishmania, Parasites, Leishmaniasis, Visceral, Leishmaniasis Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
One of the major reasons behind the limited success of vaccine candidates against all forms of leishmaniasis is the inability of parasitic antigens to induce robust cell-mediated immunity and immunological memory. Here we find, for the first time, that the adjuvantation of whole-killed Leishmania vaccine (Leishvacc) with anti-CD200 and anti-CD300a antibodies enhances CD4+ T cells mediated immunity in vaccinated mice and provides protection against wild-type parasites. The antibody adjuvantation, either alone or with a TLR4 agonist monophosphoryl A (MPL-A), induced the production of pro-inflammatory cytokines viz., IFN-γ, TNF-α, and IL-2 by antigen experienced CD4+ T cells, and also enhanced their rate of conversion into their memory phenotypes against Leishvacc antigens. The antibody adjuvanted vaccine also promoted the generation of IgG2a-mediated protective humoral immunity in vaccinated mice. Further, the mice vaccinated with antibodies adjuvanted vaccine showed strong resilience against metacyclic forms of L. donovani parasites as we observed reduced clinical features such as splenomegaly, hepatomegaly, granulomatous tissues in the liver, and parasitic load in their spleen. The findings of this study demonstrate that the anti-CD200 and anti-CD300a antibodies have potential to increase the protective efficacy of the whole-killed Leishmania vaccine, and opens up a new gateway to diversify the roles of immune checkpoints in vaccine development against leishmaniasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India.
- Centre of Experimental Medicine and Surgery, Institute of Medical Science, Banaras Hindu University, Varanasi 221005, India.
- Department of Molecular Biology, Rajendra Memorial Research Institute, Patna 800007, Bihar, India.
- ICMR-National Institute of Cholera and Enteric Diseases, Kolkata 700010, WB, India.
- Department of Biochemistry, Faculty of Science, Dr. RMLA University, Ayodhya 224001, India.
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, India. Electronic address: rakesh_bc@bhu.ac.in.
Zitieren
APA
Singh, R., Anand, A., Mahapatra, B., Saini, S., Singh, A., Singh, S., Kumar, V., Das, P., Singh, S., & Singh, R. K. (2023). Adjuvantation of whole-killed Leishmania vaccine with anti-CD200 and anti-CD300a antibodies potentiates its efficacy and provides protection against wild-type parasites. Molecular Immunology. https://doi.org/10.1016/j.molimm.2023.09.014
Vancouver
Singh R, Anand A, Mahapatra B, Saini S, Singh A, Singh S, et al. Adjuvantation of whole-killed Leishmania vaccine with anti-CD200 and anti-CD300a antibodies potentiates its efficacy and provides protection against wild-type parasites. Molecular Immunology. 2023. doi:10.1016/j.molimm.2023.09.014
BibTeX
@article{Singh2023,
author = {Singh, Rajan and Anand, Anshul and Mahapatra, Baishakhi and Saini, Shashi and Singh, Abhishek and Singh, Samer and Kumar, Vinod and Das, Pradeep and Singh, Sangram and Singh, Rakesh K},
title = {Adjuvantation of whole-killed Leishmania vaccine with anti-CD200 and anti-CD300a antibodies potentiates its efficacy and provides protection against wild-type parasites},
journal = {Molecular Immunology},
year = {2023},
doi = {10.1016/j.molimm.2023.09.014}
}
EUVIMED